Last reviewed · How we verify
NCT04820218
At-home Testing Refraction Results With Best Corrected Visual Acuity (BCVA) Outcomes in Adults
NA trial testing With Try-on glasses in Visual Impairment in 53 participants. Completed in 20 January 2023.
20 January 2023
Quick facts
| Lead sponsor | EyeQue Corp. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 53 |
| Start date | 21 April 2021 |
| Primary completion | 20 January 2023 |
| Estimated completion | 20 January 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- With Try-on glasses
Conditions studied
- Visual Impairment — all drugs for Visual Impairment →
- Myopia — all drugs for Myopia →
- Hyperopia — all drugs for Hyperopia →
- Astigmatism — all drugs for Astigmatism →
Sponsor
EyeQue Corp.
Who can join
30 and older, any sex, with Visual Impairment or Myopia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is aimed at examining the BCVA from try-on glasses constructed from measurements from the EyeQue VisionCheck.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04820218
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Visual Impairment
Currently open trials in the same condition.
- NCT06984822 — Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant · NA · recruiting
- NCT07055646 — Influence of Low Vision Assistive Technology on Mobility Among Visually Impaired Individuals · active not recruiting
- NCT06877988 — Artificial Intelligence (AI) - Assisted Visual Impairment Screening Model: Community-based Implementation and Evaluation · NA · active not recruiting
- NCT06518148 — Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification · active not recruiting
- NCT06075147 — The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impair · active not recruiting
Other EyeQue Corp. trials
Trials by the same sponsor.
- NCT04955379 — Study in Pediatric Volunteers of a Handheld Device Versus a Standard Diagnostic Device in Ophthalmic Refraction · NA · unknown
- NCT04693247 — Handheld Device Compared With a Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction · NA · unknown
- NCT04693260 — A Clinical Study to Evaluate the Remote Monitoring of Myopia Patients With the EyeQue Insight · NA · completed
- NCT04474041 — Study to Evaluate Visual Acuity Measured With the EyeQue Insight Versus a Standard Eyechart. · NA · completed
- NCT03957408 — Investigational Study of Accommodation Triggering and Control to Allow for the Performance of Refraction Measurements · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04820218 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by EyeQue Corp.
- Last refreshed: 25 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04820218.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing